From the Spectrum Healthcare Partners, South Portland, ME (AQ); Department of Anesthesiology and Perioperative Medicine, Maine Medical Center, Portland, ME (AQ, YI, JR); Translational Pain Research Department, Massachusetts General Hospital, Boston, MA (NM, GM); and Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, MA (YZ).
J Addict Med. 2023;17(6):640-645. doi: 10.1097/ADM.0000000000001191. Epub 2023 Jun 5.
Buprenorphine maintenance for opioid use disorder (OUD) can present potential challenges for acute postoperative pain management. Provider practice and consistency of buprenorphine management strategies within institutions are unknown. This study aims to identify how providers nationwide manage patients on buprenorphine when they present for elective surgery.
A prospective survey of anesthesiologists was performed nationwide between November 2021 and March 2022. Survey respondents were selected from academic institutions identified using public databases and were also distributed to online social media platforms where members are required to verify medical licensure and hospital affiliation. Survey results were calculated and interpreted as the percentage rate of response.
Survey invitations were sent to 190 institutions and returned 54 responses (28% response rate). An additional 12 completed surveys were obtained from online social media distribution resulting in 66 responses. Only 36% of respondents reported an established protocol for perioperative management of buprenorphine at their institution. Regarding consistency of buprenorphine management within institutions, the majority of respondents endorsed buprenorphine continuation without dose reduction in procedures where minimal pain was anticipated. However, there was a large discrepancy in buprenorphine management for surgeries with moderate-severe pain. Perioperative dosing frequency of buprenorphine was also inconsistent.
The majority of institutions surveyed do not have an established protocol for perioperative buprenorphine management. In addition, there is provider variability in buprenorphine dosing for procedures with moderate-severe pain. This study highlights the need for dissemination of consensus guidelines for buprenorphine management.
阿片类药物使用障碍(OUD)的丁丙诺啡维持治疗可能会给急性术后疼痛管理带来潜在挑战。医疗机构提供者的实践和丁丙诺啡管理策略的一致性尚不清楚。本研究旨在确定全国范围内的提供者在患者接受择期手术时如何管理丁丙诺啡患者。
2021 年 11 月至 2022 年 3 月期间,在全国范围内对麻醉师进行了前瞻性调查。使用公共数据库从学术机构中选择调查受访者,并将其分发给需要验证医疗执照和医院隶属关系的在线社交媒体平台。计算并解释调查结果作为回应率的百分比。
向 190 个机构发送了调查邀请,收到了 54 份回复(回应率为 28%)。通过在线社交媒体分发又获得了 12 份完整的调查回复,共收到 66 份回复。只有 36%的受访者报告他们所在机构有围手术期丁丙诺啡管理的既定方案。关于机构内丁丙诺啡管理的一致性,大多数受访者赞成在预计疼痛最小的手术中继续使用丁丙诺啡而不减少剂量。然而,对于中度至重度疼痛的手术,丁丙诺啡管理存在很大差异。丁丙诺啡围手术期的给药频率也不一致。
调查的大多数机构没有围手术期丁丙诺啡管理的既定方案。此外,在中度至重度疼痛的手术中,丁丙诺啡的剂量存在提供者差异。本研究强调了传播丁丙诺啡管理共识指南的必要性。